The global landscape for therapeutics targeting IgG4-related disease is witnessing substantial expansion. Driven by an growing prevalence of these autoimmune conditions and the presence of novel treatment solutions, the market is poised for significant prospects in the foreseeable future. Key factors fueling this growth include a rising awareness o